Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI3014 in advanced solid tumors
NCT06974812Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2025
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3014 in solid tumor, sponsored by Innovent Biologics. Started Apr 2025; status: recruiting.
02
Drugs
IBI3014
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06974812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974812.